Skip to main content
. 2016 Jan 5;6:18751. doi: 10.1038/srep18751

Figure 1. FXR promotes proliferation of tumor cell lines.

Figure 1

(A–C) Dose-dependent effect of FXR agonists in the proliferation of HepG2 cells. (A) HepG2 cells were treated with different concentrations of GW4064. (B) The proliferation of HepG2 cells was investigated using the BrdU Proliferation Kit after treatment with GW4064 or CDCA. (C) HepG2 cells were treated with different concentration of CDCA. (D) Dose-response for FXR agonist GW4064 combined with the treatment of 10 μΜ FXR antagonist (Z)-Guggulsterone (GS). HepG2 cells were treated with 10 μΜ GS together with different concentrations of GW4064. (E) HepG2 cells were treated with FXR siRNA or negative siRNA. (F) HepG2 cells were treated with FXR siRNA or negative siRNA before treatment with GW4064 or vehicle. Values of all MTT assays are presented as mean ± SD (n = 6; *P < 0.05; **P < 0.01; ***P < 0.001).